Over 11,000 people in the U.S. are diagnosed with acute myeloid leukemia (AML) each year and despite attempts to improve therapy, the overall 5-year survival remains 26% largely due to a high rate of relapse 1 . Defining the mechanisms responsible for persistence of the malignant clone is essential to improve outcome in AML.
Activation of WNT signaling pathways through nuclear localization of β -catenin has been linked to development and progression of acute myeloid leukemia (AML) 2, 3 . It is well known that nuclear translocation of These data, combined with the clinical observation that increased canonical WNT signaling in AML blasts at diagnosis is associated with decreased rates of relapse-free and overall survival, suggested a potential clinical benefit for WNT suppression 5, 6 . While this approach has shown promise in the treatment of AML, questions remain as to which sub-types of AML will benefit 7, 8 .
In this study, we characterize activation of the canonical Wnt pathway in a cohort of patients with AML and found that while a majority of patients at diagnosis showed predominantly nuclear β -catenin, treatment of primary samples with a next-generation WNT inhibitor had variable effects on blast survival and phenotype. Together, these data highlight the inherent challenges in targeting the WNT pathway in AML and emphasize that this strategy will require identification of sub-types of AML, or even individual patients, that will most benefit from this approach.
To identify such patients, we utilized multispectral imaging flow cytometry technology to quantify nuclear localization of β -catenin, the biochemical hallmark of WNT pathway activation. Thus, these findings highlight the fact that additional work is necessary to identify those clinical subsets of AML patients most susceptible to anti-WNT therapy. Figure 1 . Characteristics of samples from patients who relapsed and were available for analysis in Figure 4 are also shown. BM= bone marrow; NA = sample not available for analysis (either due to unavailability of sample or that the patient did not relapse); ND = not done. 
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